HC Wainwright & Co. Reiterates Buy on CymaBay Therapeutics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on CymaBay Therapeutics (NASDAQ:CBAY), maintaining a price target of $19.
August 10, 2023 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CymaBay Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co., with a maintained price target of $19.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for CymaBay Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100